Hyperhomocysteinemia in end-stage renal failure

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• End-stage renal disease (ESRD) patients face significantly higher risks of cardiovascular disease (CVD) mortality and morbidity.
• Myocardial infarction and stroke event rates are 5-10 times higher in ESRD patients undergoing maintenance dialysis compared to the general population.
• Hyperhomocysteinemia is a prevalent risk factor in ESRD, exceeding the commonality of traditional CVD risk factors.

Purpose of the Study:

• To highlight the prevalence and detrimental effects of hyperhomocysteinemia in end-stage renal disease patients.
• To discuss the mechanisms by which homocysteine contributes to cardiovascular complications in ESRD.
• To evaluate the efficacy of current treatment strategies and suggest potential therapeutic avenues.

Main Methods:

• Review of existing evidence on hyperhomocysteinemia in ESRD.
• Analysis of homocysteine's biochemical effects on endothelial cells and vascular function.
• Assessment of current treatment regimens, including folic acid supplementation.
• Consideration of alternative therapeutic agents like N-acetylcysteine.

Main Results:

• Homocysteine impairs nitric oxide production and endothelium-dependent vasodilation.
• Homocysteine promotes the formation of foam cells and platelet aggregation.
• Homocysteine reduces endothelial antithrombotic activity.
• Pharmacological doses of folic acid (5-15 mg/day) often lead to suboptimal reduction in homocysteine levels.

Conclusions:

• Hyperhomocysteinemia is a critical, under-addressed CVD risk factor in ESRD patients.
• Current folic acid treatments are frequently insufficient for effective homocysteine reduction.
• Further investigation into alternative therapies, such as N-acetylcysteine, is warranted for managing hyperhomocysteinemia in ESRD.